Sichen Di

Sichen Di

Auto-generated profile, based on publicly available information

Sichen Di

Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200092, P. R. China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2025 in Science Advances
Verified
Journal Article
Open access
WYWei Yang
Wei Yang
SDSichen Di
Sichen Di
ZYZihuan Yang
Zihuan Yang
JCJianwei Cao
Jianwei Cao
QFQingqiao Fu
Qingqiao Fu
XCXingang Cui
Xingang Cui
Cancer immunotherapies rely on CD8 + cytolytic T lymphocytes (CTLs) in recognition and eradication of tumor cells via antigens presented on major histocompatibility complex class I (MHC-I) molecules. However, we observe MHC-I deficiency in human and murine urologic tumors, posing daunting challenges for successful immunotherapy. We herein report an unprecedented nanosonosensitizer of one-dimensional bamboo-like multisegmented manganese dioxide@manganese–bismuth vanadate (BMMBV) to boost multiple branches of immune responses targeting MHC-I–deficient tumors. BMMBV markedly augments sonodynamic activity contributed by manganese heteroatoms in the lattice of bismuth vanadate with narrowing bandgaps. Under sonoirradiation, BMMBV enhances tumor antigen spreading and emission of adjuvant signals, which potentiate dendritic cell maturation, thereby eliciting high aptitude of CTLs. This therapy substantially up-regulates MHC expression on tumor cells, which are reversely sensitive to CTLs. Alongside, extensive innate immune cells complement the cytolytic activity of CTLs for eliminating mouse urologic tumors. This study offers a reinforced strategy against antigen-loss immune-evasive tumor.

25 April 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
SDSichen di
Sichen di
JLJi Liu
Ji Liu
ZGZhuoran Gu
Zhuoran Gu
CJChengqi Jin
Chengqi Jin
JZJunfeng Zhang
Junfeng Zhang
XYXudong Yao
Xudong Yao
ObjectiveTo investigate the molecular mechanisms of lipid metabolic reprogramming promoting tyrosine kinase inhibitors (TKIs) resistance in renal cell carcinoma (RCC).MethodsTo establish a sunitinib resistant renal cell carcinoma cell line (786O-R) and screen out arachidonic acid 5-lipoxygenase (ALOX5), a key gene regulating lipid metabolism, by transcriptome sequencing. To explore the expression of ALOX5 in TKI-resistant RCC tissues and cells, and the relationship between ALOX5 expression and the prognosis of RCC patients through databases and clinical samples. To explore the effect of ALOX5 on the nausea biological behavior of RCC cells and drug resistance to sunitinib in vitro. Transcriptome sequencing and molecular experiments were performed to explore the molecular mechanism of ALOX5 regulating lipid metabolism. The effect of ALOX5 inhibition on the tumorigenesis of 786O-R cells was investigated by animal experiments.ResultsALOX5 is upregulated in TKI-resistant RCC tissues and cells. High ALOX5 expression is associated with poor prognosis of patients with RCC. Overexpression of ALOX5 can enhance the proliferation, migration, invasion and sunitinib resistance of 786O-R cell. ALOX5 promotes sunitinib resistance in 786O-R cell by regulating lipid metabolism through the p38/ERK/PPARα pathway. Inhibition of ALOX5 inhibited the growth of subcutaneous tumors and lung metastases in 786O-R cell.ConclusionALOX5 promotes sunitinib resistance in RCC by promoting lipid metabolism through the p38/ERK/PPARα pathway. Inhibition of ALOX5 may be a potential therapeutic target for intervention of metabolic abnormalities and overcoming resistance to targeted therapy in RCC.

18 September 2026 in Drug Resistance Updates
Verified
Journal Article
Closed access
ZGZixuan Gong
Zixuan Gong
KDKeqin Dong
Keqin Dong
WCWenjin Chen
Wenjin Chen
YLYifan Liu
Yifan Liu
MLMuchen Li
Muchen Li
XCXingang Cui
Xingang Cui

3 May 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
SDSichen di
Sichen di
TWTong Wu
Tong Wu
JLJi Liu
Ji Liu
SLShuai Liu
Shuai Liu
KLKeqiang Li
Keqiang Li
HZHaimin Zhang
Haimin Zhang
ObjectiveAbnormal fatty acid metabolism drives clear cell renal cell carcinoma (ccRCC) occurrence, progression, and tyrosine kinase inhibitor (TKI) resistance, with unclear regulatory mechanisms. To investigate the role and molecular mechanism of fatty acid metabolism key gene LGALS1 in ccRCC malignant progression and TKI resistance.MethodsLGALS1 was screened via TCGA-KIRC and fatty acid metabolism gene sets. Its expression, association with ccRCC prognosis, and effects on cell behaviors, fatty acid metabolism, and sunitinib resistance were evaluated using clinical samples, in vitro experiments, transcriptome sequencing, targeted lipid metabolomics, and animal models. The correlation between LGALS1 and CPT1A on clinical outcomes was explored through a clinical cohort.ResultsHigh LGALS1 correlated with advanced stage, high grade, metastasis, and poor ccRCC prognosis. LGALS1 overexpression enhanced cell proliferation, migration, invasion, lipid accumulation, and sunitinib resistance by activating p38/ERK to inhibit PPARα and CPT1A. LGALS1 inhibition enhanced fatty acid oxidation, reversed resistance, and suppressed tumorigenesis.ConclusionsLGALS1 is a prognostic marker and potential therapeutic target for intervening ccRCC metabolic abnormalities and overcoming TKI resistance.